HOME >> MEDICINE >> NEWS
Daniel Zheng wins SIAM's first prize at INTEL-ISEF

Daniel Zheng, an eleventh grader at St. Paul Academy and Summit School in St. Paul, Minnesota was awarded first prize in SIAM's Special Awards Organizations at the INTEL International Science and Engineering Fair (ISEF) held in Indianapolis, Indiana, May 7 12, 2006.

Established in 2006, the SIAM award recognizes the projects that explore the ties between mathematics and applications that may not easily fit within a formal engineering, science, or mathematical discipline. Projects that include non-trivial mathematical analysis in the context of an engineering or science problem are considered. Examples of qualifying projects include mathematical analysis of a problem in science or engineering; projects that bridge the gap between math and an application; mathematical methods applied to solving a problem in science or engineering, optimization, scientific computing; or numerical analysis.

Zheng received the prize in recognition of his project titled "Mathematical Modeling of Smoking Effect on Down Syndrome." His entry, which examined the long term effects of smoking on the incidence of Down Syndrome, impressed Kelly Black, a judge and Associate Professor of Mathematics at Union College of Schenectady, New York.

"Mr. Zheng was able to clearly describe the mathematical model and explain the motivations as to how certain terms in the equations had been simplifiedhis project made use of a wide range of skills and techniques," says Black.

"I was partly inspired to select this topic because of my father," says Zheng. "He has done some research in the field of birth defects. I was also motivated to look into this topic by curiosity. Not a lot is known about maternal-age-related defects and I thought that with mathematics I could provide some insight into the problem."

The eleventh grader plans to write and submit an article on his project for publication in a peer-reviewed medical journal. Chang-Jiang (C.J.) Zheng, a physician specia
'"/>

Contact: Michelle Montgomery
montgomery@siam.org
215-382-9800
Society for Industrial and Applied Mathematics
1-Jun-2006


Page: 1 2 3

Related medicine news :

1. Daniel Rader, MD, of PENN, selected to direct a 2006 Freedom to Discover biomedical research grant
2. RAND presents first Victor Fuchs Research Award to economists at Carnegie Mellon University
3. Worcester Polytechnic Institute to host national forum on locating first responders inside buildings
4. Screening for behavioral health first step to getting treatment
5. Polish journalist scoops first prize in prestigious European award
6. Poker match pits an vs. machine in world first match
7. Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
8. World first medical treatment announced by researchers
9. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
10. A first glimpse at healthy brain and behavioral development
11. UPMC performs first beating heart transplant procedure in the US

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Daniel Zheng wins SIAM first prize INTEL ISEF

(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... or the removal of the adenoids and tonsils, is ... often as a treatment for children with obstructive sleep ... child,s attention and executive functioning, behavior, sleep apnea symptoms, ... until now. A study led by Susan Redline, ... and Cardiovascular Medicine and Associate Clinic Director of the ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
Breaking Medicine News(10 mins):Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) ... design, manufacture and sale of medical devices and in the ... Jun Ma , President and CEO of ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...   BCC,s aim ... synopsis of the current and future characteristics ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: